3 recruiting, 2 terminated, 1 completed, 1 unknown. 4 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 2, Terminated 1, Withdrawn 1 |
| Phase 2 | 4 | Completed 1, Recruiting 1, Terminated 1, Withdrawn 1 |
Follow Castration Resistant Prostatic Cancer: new trials by email Literature Review of Castration Resistant Prostatic Cancer trials Research Report on Castration Resistant Prostatic Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of MGC026 in Participants With Advanced Solid Tumors MGC026 Dose Escalation, MGC026 Dose for Expansion, Pembrollizumab - Advanced Solid Tumor, Advanced Cancer | Phase 1 | Recruiting | MacroGenics | 394 | 2024-03-06 | 2026-10-28 |
| Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) JANX007, Darolutamide - Prostate Cancer, Metastatic Castration-resistant Prostate Cancer | Phase 1 | Recruiting | Janux Therapeutics | 272 | 2022-09-15 | 2026-10-29 |
| Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC NUV-422, Enzalutamide - Prostate Cancer, Prostatic Cancer | Phase 1 / Phase 2 | Withdrawn | Nuvation Bio Inc. | 2022-09-01 | 2022-08-05 | |
| Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer Docetaxel intermittent - Castration Resistant Prostatic Cancer | Phase 2 | Terminated | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 6 | 2022-07-29 | 2024-11-22 |
| NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors NUV-868, Olaparib, Enzalutamide - Advanced Solid Tumor, Ovarian Cancer | Phase 1 | Terminated | Nuvation Bio Inc. | 82 | 2022-03-29 | 2025-11-06 |
| Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer Omeprazole 80 mg twice daily - Prostate Cancer, Refractory Cancer | Phase 2 | Recruiting | Wake Forest University Health Sciences | 50 | 2021-03-05 | 2026-04-13 |
| Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects Pembrolizumab, Chemotherapy - Castration Resistant Prostatic Cancer, Metastatic Prostate Cancer | Phase 2 | Completed | University of California, San Francisco | 26 | 2018-02-20 | 2024-11-20 |
| Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study) Prostate Cancer Metastatic, Castration Resistant Prostatic Cancer | Unknown | Universität des Saarlandes | 500 | 2016-01-01 | 2022-12-08 |
Prostatic Neoplasms, Castration-Resistant (8) · Prostatic Neoplasms (5) · Breast Neoplasms (2) · Ovarian Neoplasms (2) · Pancreatic Neoplasms (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Melanoma (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Sarcoma (1)
Genital Diseases (8) · Genital Diseases, Male (8) · Genital Neoplasms, Male (8) · Male Urogenital Diseases (8) · Neoplasms by Site (8) · Prostatic Diseases (8) · Urogenital Diseases (8) · Urogenital Neoplasms (8) · Neoplasms (7) · Prostatic Neoplasms (3) · Adnexal Diseases (2) · Breast Diseases (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Endocrine Gland Neoplasms (2)
enzalutamide (2) · pembrolizumab (2) · Drug Therapy (1) · Omeprazole (1) · darolutamide (1) · olaparib (1)
Nuvation Bio Inc. (2) · Australian and New Zealand Urogenital and Prostate Cancer Trials Group (1) · Janux Therapeutics (1) · MacroGenics (1) · University of California, San Francisco (1) · Universität des Saarlandes (1) · Wake Forest University Health Sciences (1)
United States (6) · Australia (4) · Germany (1) · Spain (1) · United Kingdom (1)
David Oh, MD (1) · Kate Mahon (1) · Michael Goodman, MD (1) · Samer Ezziddin, MSc, MD, PhD (1) · Yiyun Dai, MD, PhD (1)
PMID 37889298, PMID 38769643, PMID 39008067, PMID 40619537
P30CA012197 (1), R01CA223484 (1)